ACOG
Alpha Cognition Inc. Common Stock NASDAQ Listed Nov 12, 2024$7.89
+1.28%
vs $7.79
Mkt Cap $122.5M
52w Low $4.50
48.2% of range
52w High $11.54
50d MA $6.25
200d MA $6.20
P/E (TTM)
—
EV/EBITDA
—
P/B
2.2x
Debt/Equity
0.0x
ROE
-33.1%
P/FCF
-6.7x
RSI (14)
83.40
ATR (14)
$0.54
Beta
2.52
50d MA
$6.25
200d MA
$6.20
Avg Volume
40.5K
Alpha Cognition Inc., a clinical stage biopharmaceutical company, engages in the development of treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company offers ZUNVEYL (benzgalantamine) for the treatment of mild-to-moderate Alzheimer's disease and mild traumatic brain injury. It also develops ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.
750 West Pender Street · Vancouver, BC V6C 2T8 · CA
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | AMC | -0.27 | -0.30 | -11.1% | 5.34 | -6.2% | -4.9% | +4.7% | +3.2% | +8.6% | +0.3% | — |
| Nov 13, 2025 | AMC | -0.43 | -0.30 | +30.2% | 6.13 | -2.1% | -3.1% | -0.7% | +5.6% | -5.0% | -1.5% | — |
| Aug 14, 2025 | AMC | -0.46 | -0.65 | -41.3% | 8.00 | +6.5% | +0.0% | +5.6% | -4.3% | -1.1% | +3.2% | — |
| May 15, 2025 | AMC | -0.58 | -0.20 | +65.5% | 6.81 | +5.0% | +27.0% | +15.6% | +5.8% | -6.9% | -11.8% | — |
| Mar 31, 2025 | AMC | -0.48 | -0.51 | -6.2% | 5.06 | +3.8% | -4.2% | +4.7% | -1.8% | -3.2% | -8.3% | — |
| Nov 14, 2024 | AMC | -1.00 | -0.31 | +69.0% | 5.68 | -1.4% | -5.5% | +6.1% | -0.7% | +2.1% | -0.5% | — |
| Aug 12, 2024 | AMC | -1.00 | -0.35 | +64.8% | — | — | — | — | — | — | — | — |
| Mar 31, 2024 | AMC | — | -0.87 | — | — | — | — | — | — | — | — | — |
| Dec 31, 2023 | AMC | — | -1.55 | — | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | AMC | — | -0.84 | — | — | — | — | — | — | — | — | — |
| Jun 30, 2023 | AMC | — | -0.74 | — | — | — | — | — | — | — | — | — |
| Mar 31, 2023 | AMC | — | -0.60 | — | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 29 | Maxim Group | Initiates | Buy | $12 | $5.94 | $5.97 | +0.5% | +4.2% | +2.4% | -2.5% | -1.6% | -2.8% |
| Apr 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.86 | $6.75 | -1.6% | -6.3% | -3.6% | -5.3% | +1.7% | -0.3% |
| Dec 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.05 | $5.05 | +0.0% | +10.1% | +8.6% | -1.2% | +4.7% | +0.3% |
| Oct 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.80 | $6.82 | +0.3% | +4.9% | -3.9% | +0.7% | +1.3% | -1.7% |
| May 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.81 | $7.15 | +5.0% | +27.0% | +15.6% | +5.8% | -6.9% | -11.8% |
| Apr 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.06 | $5.25 | +3.8% | -4.2% | +4.7% | -1.8% | -3.2% | -8.3% |
| Mar 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.53 | $5.41 | -2.2% | -8.5% | -4.2% | +4.7% | -1.8% | -3.2% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 26, 2026 | Opaleye Management Inc.10% | — | Buy | 152,336 | $6.40 | $975K | 2,805,107 | +6.02% | — |
| Jun 25, 2026 | Opaleye Management Inc.10% | — | Buy | 197 | $6.50 | $1K | 2,652,771 | +6.02% | — |
| Jun 15, 2026 | Opaleye Management Inc.10% | — | Buy | 4,550 | $5.99 | $27K | 2,652,574 | +0.33% | -2.74% |
| Jun 12, 2026 | Opaleye Management Inc.10% | — | Buy | 273 | $5.93 | $2K | 2,648,024 | +0.33% | -2.74% |
| Jun 11, 2026 | Opaleye Management Inc.10% | — | Buy | 2,862 | $5.91 | $17K | 2,647,751 | +0.33% | -2.74% |
| Jun 10, 2026 | Opaleye Management Inc.10% | — | Buy | 5,872 | $5.99 | $35K | 2,644,889 | -0.83% | +3.44% |
| Jun 9, 2026 | Opaleye Management Inc.10% | — | Buy | 24,856 | $5.98 | $149K | 2,639,017 | -0.83% | +3.44% |
| Jun 5, 2026 | Opaleye Management Inc.10% | — | Buy | 10,054 | $5.83 | $59K | 2,614,161 | -0.17% | +0.33% |
| May 19, 2026 | D'Angelo Lauren | Chief Operating Officer | Buy | 3,500 | $5.76 | $20K | 140,695 | +1.55% | -2.55% |
| May 18, 2026 | Opaleye Management Inc.10% | — | Buy | 17,395 | $5.69 | $99K | 2,505,993 | +1.55% | -2.55% |
| May 15, 2026 | Opaleye Management Inc.10% | — | Buy | 16,648 | $5.83 | $97K | 2,488,598 | +1.55% | -2.55% |
8-K · 5.02
!!! Very High
Alpha Cognition Inc. -- 8-K 5.02: Executive Change
Jun 23
8-K · 5.02
!!! Very High
Alpha Cognition Inc. -- 8-K 5.02: Executive Change
Alpha Cognition Inc. (ACOG) appointed Bethany Sensenig as a director, expanding its board composition and potentially bringing new expertise to guide the company's strategic direction.
Apr 20
8-K · 5.02
!!! Very High
Emmaus Life Sciences, Inc. -- 8-K 5.02: Executive Change
Emmaus Life Sciences appointed Henry H. Du and Jon Kuwahara as Vice Presidents, strengthening its executive team with two new leadership additions.
Apr 17
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
ACOG acquired Memogain assets from Galantos Pharma, potentially expanding its product portfolio and revenue streams, which could strengthen competitive positioning and drive near-term growth.
Apr 14
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Alpha Cognition's March 27, 2026 record date announcement suggests an upcoming dividend or shareholder distribution, which could indicate management confidence in cash flow sustainability and provide income to shareholders, though investors should monitor if distributions strain balance sheet strength.
Mar 27
8-K
Unknown — 8-K Filing
Alpha Cognition reported 2025 full-year results; investors should monitor cash runway, clinical trial progress, and burn rate given the company's pre-revenue biotech status and development stage.
Mar 26
8-K · 5.02
!!! Very High
Alpha Cognition Inc. -- 8-K 5.02: Executive Change
The departure of a key executive at Alpha Cognition signals potential leadership uncertainty that could impact operational continuity and investor confidence, warranting close monitoring of the replacement announcement and strategic direction.
Feb 23
Valuation
Market Cap
$122.5M
Enterprise Value
$73.4M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.13x
P/B
2.23x
P/S
12.89x
P/FCF
-6.75x
EV/EBITDA
—
Shares Out
17.7M
Financials (TTM)
Revenue
$10.8M
Net Income
-$25.1M
EBITDA
-$27.0M
Free Cash Flow
-$20.7M
Op Cash Flow
-$20.4M
EPS Basic
$-1.17
EPS Diluted
$-1.36
EPS Forward
$-1.34
Gross Margin
84.4%
Op Margin
-250.0%
Net Margin
-232.2%
Balance Sheet
Total Assets
$79.7M
Total Liab.
$17.2M
Total Equity
$62.5M
Cash
$66.1M
LT Debt
$0
Book Value/Sh
$3.54
Debt/Equity
0.00x
Current Ratio
8.65
Quick Ratio
8.09
Returns & Growth
ROE
-33.1%
ROA
-25.9%
ROIC
-32.1%
Rev Growth YoY
+0.0%
EPS Growth YoY
+42.1%
Price Returns
2W
+18.1%
1M
+29.8%
3M
+27.3%
6M
+21.4%
12M
-24.6%
Technicals
52W High
$11.54
52W Low
$4.50
50d MA
$6.25
200d MA
$6.20
RSI (14)
83.40
ATR (14)
$0.54
Beta
2.52
Avg Volume
41K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$14.00
High
$14.00
Low
$14.00
Median
$14.00
Data updated apr 24, 2026 10:39am
· Source: financialmodelingprep.com